

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|---|---|--|
| 1. Name and Address of Reporting Person* <u>KAZIMI A J</u> (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950 (Street) NASHVILLE TN 37203 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [CPIX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chairman and CEO |
| | 3. Date of Earliest Transaction (Month/Day/Year) 07/01/2021 | |
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 07/01/2021 | | P | | 15 ⁽¹⁾ | A | \$2.91 | 5,768,529 | D | |
| Common Stock | 07/02/2021 | | P | | 15 ⁽¹⁾ | A | \$2.94 | 5,768,544 | D | |
| Common Stock | 07/06/2021 | | P | | 15 ⁽¹⁾ | A | \$3.14 | 5,768,559 | D | |
| Common Stock | 07/07/2021 | | P | | 15 ⁽¹⁾ | A | \$3.21 | 5,768,574 | D | |
| Common Stock | 07/08/2021 | | P | | 15 ⁽¹⁾ | A | \$3.18 | 5,768,589 | D | |
| Common Stock | 07/09/2021 | | P | | 15 ⁽¹⁾ | A | \$3.13 | 5,768,604 | D | |
| Common Stock | 07/12/2021 | | P | | 15 ⁽¹⁾ | A | \$3.33 | 5,768,619 | D | |
| Common Stock | 07/13/2021 | | P | | 15 ⁽¹⁾ | A | \$3.48 | 5,768,634 | D | |
| Common Stock | 07/14/2021 | | P | | 15 ⁽¹⁾ | A | \$3.33 | 5,768,649 | D | |
| Common Stock | 07/15/2021 | | P | | 15 ⁽¹⁾ | A | \$3.27 | 5,768,664 | D | |
| Common Stock | 07/16/2021 | | P | | 15 ⁽¹⁾ | A | \$3.28 | 5,768,679 | D | |
| Common Stock | 07/19/2021 | | P | | 15 ⁽¹⁾ | A | \$3.23 | 5,768,694 | D | |
| Common Stock | 07/20/2021 | | P | | 15 ⁽¹⁾ | A | \$3.24 | 5,768,709 | D | |
| Common Stock | 07/21/2021 | | P | | 15 ⁽¹⁾ | A | \$3.26 | 5,768,724 | D | |
| Common Stock | 07/22/2021 | | P | | 15 ⁽¹⁾ | A | \$3.36 | 5,768,739 | D | |
| Common Stock | 07/23/2021 | | P | | 15 ⁽¹⁾ | A | \$3.35 | 5,768,754 | D | |
| Common Stock | 07/26/2021 | | P | | 15 ⁽¹⁾ | A | \$3.41 | 5,768,769 | D | |
| Common Stock | 07/27/2021 | | P | | 15 ⁽¹⁾ | A | \$3.39 | 5,768,784 | D | |
| Common Stock | 07/28/2021 | | P | | 15 ⁽¹⁾ | A | \$3.42 | 5,768,799 | D | |
| Common Stock | 07/29/2021 | | P | | 15 ⁽¹⁾ | A | \$3.42 | 5,768,814 | D | |
| Common Stock | 07/30/2021 | | P | | 15 ⁽¹⁾ | A | \$3.31 | 5,768,829 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | |

Explanation of Responses:

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.

Remarks:

A.J. Kazimi by /s/ John Hamm 09/10/2021
as attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.